Cargando…
Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis
Misunderstanding temporal coincidence of adverse events during mass vaccination and invalid assessment of possible safety concerns have negative effects on immunization programs, leading to low immunization coverage. We conducted this systematic review and meta-analysis to identify the incidence rat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850251/ https://www.ncbi.nlm.nih.gov/pubmed/35185881 http://dx.doi.org/10.3389/fimmu.2022.782198 |
_version_ | 1784652553686876160 |
---|---|
author | Wang, Fengge Wang, Donglan Wang, Yingjie Li, Cancan Zheng, Yulu Guo, Zheng Liu, Pengcheng Zhang, Yichun Wang, Wei Wang, Youxin Hou, Haifeng |
author_facet | Wang, Fengge Wang, Donglan Wang, Yingjie Li, Cancan Zheng, Yulu Guo, Zheng Liu, Pengcheng Zhang, Yichun Wang, Wei Wang, Youxin Hou, Haifeng |
author_sort | Wang, Fengge |
collection | PubMed |
description | Misunderstanding temporal coincidence of adverse events during mass vaccination and invalid assessment of possible safety concerns have negative effects on immunization programs, leading to low immunization coverage. We conducted this systematic review and meta-analysis to identify the incidence rates of GBS that are temporally associated with viral vaccine administration but might not be attributable to the vaccines. By literature search in Embase and PubMed, we included 48 publications and 2,110,441,600 participants. The pooled incidence rate of GBS was 3.09 per million persons (95% confidence interval [CI]: 2.67 to 3.51) within six weeks of vaccination, equally 2.47 per 100,000 person-year (95%CI: 2.14 to 2.81). Subgroup analyses illustrated that the pooled rates were 2.77 per million persons (95%CI: 2.47 to 3.07) for individuals who received the influenza vaccine and 2.44 per million persons (95%CI: 0.97 to 3.91) for human papillomavirus (HPV) vaccines, respectively. Our findings evidence the GBS-associated safety of virus vaccines. We present a reference for the evaluation of post-vaccination GBS rates in mass immunization campaigns, including the SARS-CoV-2 vaccine. |
format | Online Article Text |
id | pubmed-8850251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88502512022-02-18 Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis Wang, Fengge Wang, Donglan Wang, Yingjie Li, Cancan Zheng, Yulu Guo, Zheng Liu, Pengcheng Zhang, Yichun Wang, Wei Wang, Youxin Hou, Haifeng Front Immunol Immunology Misunderstanding temporal coincidence of adverse events during mass vaccination and invalid assessment of possible safety concerns have negative effects on immunization programs, leading to low immunization coverage. We conducted this systematic review and meta-analysis to identify the incidence rates of GBS that are temporally associated with viral vaccine administration but might not be attributable to the vaccines. By literature search in Embase and PubMed, we included 48 publications and 2,110,441,600 participants. The pooled incidence rate of GBS was 3.09 per million persons (95% confidence interval [CI]: 2.67 to 3.51) within six weeks of vaccination, equally 2.47 per 100,000 person-year (95%CI: 2.14 to 2.81). Subgroup analyses illustrated that the pooled rates were 2.77 per million persons (95%CI: 2.47 to 3.07) for individuals who received the influenza vaccine and 2.44 per million persons (95%CI: 0.97 to 3.91) for human papillomavirus (HPV) vaccines, respectively. Our findings evidence the GBS-associated safety of virus vaccines. We present a reference for the evaluation of post-vaccination GBS rates in mass immunization campaigns, including the SARS-CoV-2 vaccine. Frontiers Media S.A. 2022-02-03 /pmc/articles/PMC8850251/ /pubmed/35185881 http://dx.doi.org/10.3389/fimmu.2022.782198 Text en Copyright © 2022 Wang, Wang, Wang, Li, Zheng, Guo, Liu, Zhang, Wang, Wang and Hou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Fengge Wang, Donglan Wang, Yingjie Li, Cancan Zheng, Yulu Guo, Zheng Liu, Pengcheng Zhang, Yichun Wang, Wei Wang, Youxin Hou, Haifeng Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis |
title | Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis |
title_full | Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis |
title_fullStr | Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis |
title_full_unstemmed | Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis |
title_short | Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis |
title_sort | population-based incidence of guillain-barré syndrome during mass immunization with viral vaccines: a pooled analysis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850251/ https://www.ncbi.nlm.nih.gov/pubmed/35185881 http://dx.doi.org/10.3389/fimmu.2022.782198 |
work_keys_str_mv | AT wangfengge populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT wangdonglan populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT wangyingjie populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT licancan populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT zhengyulu populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT guozheng populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT liupengcheng populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT zhangyichun populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT wangwei populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT wangyouxin populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis AT houhaifeng populationbasedincidenceofguillainbarresyndromeduringmassimmunizationwithviralvaccinesapooledanalysis |